Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

High-dose erythropoietin for tissue protection

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. A totally new system is needed for drug research and development

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  2. Patients not patents: Drug research and development as a public enterprise

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prediction of coronary heart disease or heart failure using high-sensitivity cardiac troponin T: a pilot study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Anti-inflammatory effects of exercise: role in diabetes and cardiovascular disease

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  5. Familial hypercholesterolaemia: cholesterol efflux and coronary disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Electro convulsive therapy: Modification of its effect on the autonomic nervous system using anti-cholinergic drugs

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Interindividual and regional relationship between cerebral blood flow and glucose metabolism in the resting brain

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Neuronal nitric oxide inhibition attenuates the protective effect of HBO2 during cyanide poisoning

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The influence of the anesthesia-to-stimulation time interval on seizure quality parameters in electroconvulsive therapy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: The discovery of potential anti-apoptotic and cytoprotective effects of recombinant human erythropoietin (rHuEPO) has led to clinical trials investigating the use of high-dose, short-term rHuEPO therapy for tissue protection in conditions such as stroke and myocardial infarction. Experimental studies have been favourable, but the clinical efficacy has yet to be validated.

MATERIALS AND METHODS: We have reviewed clinical studies regarding the use of high-dose, short-term rHuEPO therapy for tissue protection in humans with the purpose to detail the safety and efficacy of rHuEPO for this indication. A systematic literature search was performed using the PubMed/MEDLINE database for randomized, placebo-controlled clinical trials.

RESULTS: Twenty-six randomized controlled trials that enrolled 3176 patients were included. The majority of trials (20 trials including 2724 patients) reported no effect of rHuEPO therapy on measures of tissue protection. Five trials including 1025 patients reported safety concerns in the form of increased mortality or adverse event rates. No studies reported reduced mortality.

CONCLUSIONS: Evidence is sparse to support a tissue-protective benefit of rHuEPO in humans. Moreover, a number of studies indicate that short-term administration of high-dose rHuEPO is associated with an increased risk of mortality and serious adverse events. Further work is needed to elucidate the mechanisms of toxicity of rHuEPO in humans.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Clinical Investigation
Vol/bind44
Udgave nummer12
Sider (fra-til)1230-8
Antal sider9
ISSN0014-2972
DOI
StatusUdgivet - dec. 2014

ID: 44990486